Overview

Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients

Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
Primary Objective: - To assess the safety and tolerability of escalating single and multiple doses of SAR228810 in patients with Alzheimer's disease (AD) Secondary Objective: - To evaluate the pharmacokinetic properties of SAR228810 after escalating single and multiple doses of SAR228810 in AD patients
Phase:
Phase 1
Details
Lead Sponsor:
Sanofi